Yaping Chang

Yaping Chang

Auto-generated profile, based on publicly available information

Yaping Chang

Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2019 in Journal of Clinical Epidemiology
Verified
Journal Article
Closed access
YZYuan Zhang
Yuan Zhang
PAPablo Alonso
Pablo Alonso
GGGordon H. Guyatt
Gordon H. Guyatt
JYJuan José Yepes-Nuñez
Juan José Yepes-Nuñez
EAElie A. Akl
Elie A. Akl
HSHolger J. Schünemann
Holger J. Schünemann


1 April 2020 in Journal of Bone and Joint Surgery
Verified
Journal Article
Open access
CVChristopher Vannabouathong
Christopher Vannabouathong
TDTahira Devji
Tahira Devji
SESeper Ekhtiari
Seper Ekhtiari
YCYaping Chang
Yaping Chang
SPSteven A. Phillips
Steven A. Phillips
MBMohit Bhandari
Mohit Bhandari

3 November 2020 in Annals of Internal Medicine
Verified
Journal Article
Closed access
JBJason W Busse
Jason W Busse
Behnam SadeghiradBehnam Sadeghirad
Behnam Sadeghirad
YOYvgeniy Oparin
Yvgeniy Oparin
ECEric Chen
Eric Chen
AGAnna Goshua
Anna Goshua
GGGordon H. Guyatt
Gordon H. Guyatt
This network meta-analysis of 207 trials summarizes evidence about the benefits and harms of 45 therapies for acute pain from non–low back musculoskeletal injuries. Background: Patients and clinicians can choose from several treatment options to address acute pain from non–low back musculoskeletal injuries. Purpose: To assess the comparative effectiveness of o...

1 January 2020 in Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders
Verified
Journal Article
Open access
PDF file
HJHerman Johal
Herman Johal
TDTahira Devji
Tahira Devji
YCYaping Chang
Yaping Chang
JSJonathan Simone
Jonathan Simone
CVChristopher Vannabouathong
Christopher Vannabouathong
MBMohit Bhandari
Mohit Bhandari
Background: For patients with chronic, non-cancer pain, traditional pain-relieving medications include opioids, which have shown benefits but are associated with increased risks of addiction and adverse effects. Medical cannabis has emerged as a treatment alternative for managing these patients and there has been a rise in the number of randomized clinical trials in recent years; therefore, a systematic review of the evidence was warranted. Objective: To analyze the evidence surrounding the benefits and harms of medical cannabinoids in the treatment of chronic, non-cancer-related pain. Design: Systematic review with meta-analysis. Data sources: Medline, Embase, CINAHL, SCOPUS, Google Scholar, and Cochrane Databases. Eligibility criteria: English language randomized clinical trials of cannabinoids for the treatment of chronic, non-cancer-related pain. Data extraction and synthesis: Study quality was assessed using the Cochrane risk of bias tool. All stages were conducted independently by a team of 6 reviewers. Data were pooled through meta-analysis with different durations of treatment (2 weeks, 2 months, 6 months) and stratified by route of administration (smoked, oromucosal, oral), conditions, and type of cannabinoids. Main outcomes and measures: Patient-reported pain and adverse events (AEs). Results: Thirty-six trials (4006 participants) were included, examining smoked cannabis (4 trials), oromucosal cannabis sprays (14 trials), and oral cannabinoids (18 trials). Compared with placebo, cannabinoids showed a significant reduction in pain which was greatest with treatment duration of 2 to 8 weeks (weighted mean difference on a 0-10 pain visual analogue scale −0.68, 95% confidence interval [CI], −0.96 to −0.40, I 2 = 8%, P < .00001; n = 16 trials). When stratified by route of administration, pain condition, and type of cannabinoids, oral cannabinoids had a larger reduction in pain compared with placebo relative to oromucosal and smoked formulations but the difference was not significant ( P[interaction] > .05 in all the 3 durations of treatment); cannabinoids had a smaller reduction in pain due to multiple sclerosis compared with placebo relative to other neuropathic pain ( P[interaction] = .05) within 2 weeks and the difference was not significant relative to pain due to rheumatic arthritis; nabilone had a greater reduction in pain compared with placebo relative to other types of cannabinoids longer than 2 weeks of treatment but the difference was not significant ( P[interaction] > .05). Serious AEs were rare, and similar across the cannabinoid (74 out of 2176, 3.4%) and placebo groups (53 out of 1640, 3.2%). There was an increased risk of non-serious AEs with cannabinoids compared with placebo. Conclusions: There was moderate evidence to support cannabinoids in treating chronic, non-cancer pain at 2 weeks. Similar results were observed at later time points, but the confidence in effect is low. There is little evidence that cannabinoids increase the risk of experiencing serious AEs, although non-serious AEs may be common in the short-term period following use.

1 February 2019 in JBJS Reviews
Verified
Journal Article
Closed access
YCYaping Chang
Yaping Chang
MBMohit Bhandari
Mohit Bhandari
KZKan Lun Zhu
Kan Lun Zhu
RMReza Donald Mirza
Reza Donald Mirza
MRMelody Ren
Melody Ren
Gordon H. GuyattGordon H. Guyatt
Gordon H. Guyatt
Background: Evidence with regard to antibiotic prophylaxis for patients with open fractures of the extremities is limited. We therefore conducted a systematic survey addressing current practice and recommendations.Methods: We included publications from January 2007 to June 2017. We searched Embase, MEDLINE, CINAHL, the Cochrane Central Registry of Controlled Trials (CENTRAL), and the Cochrane Database of Systematic Reviews for clinical studies and surveys of surgeons; WorldCat for textbooks; and web sites for guidelines and institutional protocols.Results: We identified 223 eligible publications that reported 100 clinical practice patterns and 276 recommendations with regard to systemic antibiotic administration, and 3 recommendations regarding local antibiotic administration alone. Most publications of clinical practice patterns used regimens with both gram-positive and gram-negative coverage and continued the administration for 2 to 3 days. Most publications recommended prophylactic systemic antibiotics. Most recommendations suggested gram-positive coverage for less severe injuries and administration duration of 3 days or less. For more severe injuries, most recommendations suggested broad antimicrobial coverage continued for 2 to 3 days. Most publications reported intravenous administration of antibiotics immediately.Conclusions: Current practice and recommendations strongly support early systemic antibiotic prophylaxis for patients with open fractures of the extremities. Differences in antibiotic regimens, doses, and durations of administration remain in both practice and recommendations. Consensus with regard to optimal practice will likely require well-designed randomized controlled trials.Clinical Relevance: The current survey of literature systematically provides surgeons’ practice and the available expert recommendations from 2007 to 2017 on the use of prophylactic antibiotics in the management of open fractures of extremities.